# A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

> **NCT05152147** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Jazz Pharmaceuticals** · enrollment: 920 (actual)

## Conditions studied

- Gastric Neoplasms
- Gastroesophageal Adenocarcinoma
- Esophageal Adenocarcinoma

## Interventions

- **DRUG:** Zanidatamab
- **DRUG:** Tislelizumab
- **DRUG:** Trastuzumab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Cisplatin
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT05152147
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-02
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 920 (ACTUAL)
- **Last updated:** 2026-04-17

## Collaborators

- BeOne Medicines LTD
- BeOne Pharmaceutical Co., Ltd.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05152147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05152147, "A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05152147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*